04:39 PM EDT, 04/03/2025 (MT Newswires) -- Sangamo Therapeutics ( SGMO ) said Thursday it signed a license agreement with Eli Lilly ( LLY ) to use its STAC-BBB adeno-associated virus capsid for diseases of the central nervous system.

The deal grants Lilly worldwide rights to use the STAC-BBB capsid for one initial target, with the option to add up to four more.

Sangamo said it will get an $18 million upfront license fee and may receive up to $1.4 billion in additional licensed target fees and milestone payments for the five potential disease targets, in addition to royalties on potential sales.

The shares of Sangamo Therapeutics ( SGMO ) were rising past 26% in after-hours activity.